NERVIANO, Italy, October 21 /PRNewswire/ -- Nerviano Medical Sciences (NMS), the largest pharmaceutical RD facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, today announced a new multi-year agreement with Genentech, Inc.
This new research agreement is the second collaboration agreement signed between Genentech and NMS in less than twelve months.
The two Companies will collaborate in the discovery of antibody drug conjugates for the development of potential anticancer agents.
Genentech, which is a leading oncology company in the United States, will have the exclusive license to fully develop and commercialize licensed products that contain such antibody drug conjugates.